Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
Add more filters










Publication year range
1.
Vet Surg ; 50(1): 104-110, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32870506

ABSTRACT

OBJECTIVE: To describe the outcome of small ruminants treated with unilateral and bilateral mastectomy by using three surgical techniques. STUDY DESIGN: Retrospective study. ANIMALS: Twenty-five small ruminants (24 goats and one sheep). METHODS: Medical records of animals that underwent mastectomy between November 1, 2002, and May 1, 2019, were reviewed. Follow-up information was obtained by telephone questionnaire with owners. Signalment, surgical data, intraoperative and postoperative complications, bacterial culture results, histopathologic diagnoses, short- and long-term outcomes, and other procedures performed were recorded. RESULT: Procedures consisted of six unilateral (with an elliptical incision) and 19 total (with inverted cloverleaf or elliptical skin incisions) mastectomies. All animals survived to hospital discharge. Intraoperative complications included contamination of the surgical site with mammary-gland fluid, hemorrhage, and difficulty dissecting skin from the mammary gland. Postoperative complications included seroma formation (7/25), surgical-site infection (5/25), and dehiscence of the skin incision (3/25). Mammary neoplasia was diagnosed in seven of 15 animals with histopathologic examination. No association was detected between surgical technique, diagnosis of neoplasia, and long-term outcome. Overall, client satisfaction was high. CONCLUSION: Mastectomy was effective at removing abnormally enlarged udders secondary to chronic mastitis, inappropriate lactation, idiopathic causes, or neoplasia and was associated with a low rate of complications in small ruminants. CLINICAL SIGNIFICANCE: Unilateral mastectomy with an elliptical skin incision or total mastectomy, preferably with inverted cloverleaf skin incision, may be indicated to remove diseased mammary tissue in small ruminants and can result in long-term survival with low morbidity and cosmetically pleasing results.


Subject(s)
Goats/surgery , Mastectomy/veterinary , Postoperative Complications/veterinary , Sheep, Domestic/surgery , Animals , Mastectomy/methods , Mastectomy, Radical/veterinary , Mastectomy, Simple/veterinary , Postoperative Complications/classification , Retrospective Studies
2.
Ups J Med Sci ; 115(2): 125-30, 2010 May.
Article in English | MEDLINE | ID: mdl-19943816

ABSTRACT

OBJECTIVES: Therapeutic monitoring of sirolimus and everolimus is necessary in order to minimize adverse side-effects and to ensure effective immunosuppression. A sirolimus-dosing model using the concentration/dose ratio has been previously proposed for kidney transplant patients, and the aim of our study was the evaluation of this single model for the prediction of trough sirolimus and everolimus concentrations. METHODS: Trough steady-state sirolimus concentrations were determined in several blood samples from each of 7 kidney and 9 liver maintenance transplant recipients, and everolimus concentrations from 20 kidney, 17 liver, and 3 kidney/liver maintenance transplant recipients. Predicted sirolimus and everolimus concentrations (Css), corresponding to the doses (D), were calculated using the measured concentrations (Css(0)) and corresponding doses (D(0)) on starting the study: Css = (Css(0))(D)/D(0). RESULTS: The diagnostic efficiency of the predicting model for the correct classification as subtherapeutic, therapeutic, and supratherapeutic values with respect to the experimentally obtained concentrations was 91.3% for sirolimus and 81.4% for everolimus in the kidney transplant patients. In the liver transplant patients the efficiency was 69.2% for sirolimus and 72.6% for everolimus, and in the kidney/liver transplant recipients the efficiency for everolimus was 67.9%. CONCLUSIONS: The model has an acceptable diagnostic efficiency (>80%) for the prediction of sirolimus and everolimus concentrations in kidney transplant recipients, but not in liver transplant recipients. However, considering the wide ranges found for the prediction error of sirolimus and everolimus concentrations, the clinical relevance of this dosing model is weak.


Subject(s)
Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation , Liver Transplantation , Sirolimus/analogs & derivatives , Sirolimus/pharmacokinetics , Adult , Aged , Dose-Response Relationship, Drug , Everolimus , Female , Humans , Male , Middle Aged
3.
Ther Drug Monit ; 31(2): 269-72, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19258927

ABSTRACT

The presence of endogenous antibodies in the serum of some patients has long been known to be a potential source of interference in immunoassays. We report falsely increased whole blood tacrolimus concentrations using the antibody conjugated magnetic immunoassay from Siemens HealthCare Diagnostics in a liver transplant recipient due to the presence of circulating endogenous antibodies (possibly heterophilic antibodies). Estimation of whole blood tacrolimus concentrations from the washed erythrocytes concentrations is proposed as a tentative approach for obtaining reliable results using the antibody conjugated magnetic immunoassay assay in these cases, leading to analogous blood tacrolimus concentrations to those produced by the microparticle enzyme immunoassay from Abbott Laboratories.


Subject(s)
Antibodies, Heterophile/blood , Immunosuppressive Agents/blood , Liver Transplantation , Tacrolimus/blood , False Positive Reactions , Humans , Immunoassay , Male , Middle Aged
4.
Ups J Med Sci ; 114(1): 55-61, 2009.
Article in English | MEDLINE | ID: mdl-19242874

ABSTRACT

BACKGROUND: Although high-performance liquid chromatography (HPLC) is the method of choice for blood sirolimus determination, the microparticle enzyme immunoassay (MEIA) run on the IMx analyser is widely used in therapeutic monitoring of this immunosuppressant agent. The aim of our study was to evaluate the possible determination of sirolimus using the fluorescence polarization immunoassay (FPIA) commercialized for everolimus quantification. METHODS: Sirolimus concentrations were determined in whole-blood samples from liver and kidney transplant recipients using the Innofluor Certican FPIA (Seradyn Inc.) run on a TDx analyser (Abbott Laboratories), Sirolimus MEIA run on an IMx analyser (Abbott Laboratories), and HPLC (UV detection) methods. RESULTS: The Innofluor FPIA has a similar cross-reactivity with everolimus and sirolimus, and the within- and between-run coefficients of variation obtained for sirolimus determination were 2.7%-13.3%. In analysing different blood samples from liver and kidney transplant patients the linear regressions obtained were: FPIA = 1.12 HPLC + 0.43 (n=104, r=0.874), MEIA = 1.14 HPLC (n=146, r=0.892), and FPIA = 1.00 MEIA + 0.29 (n=106, r=0.941). Better correlation coefficients were obtained between the methods in the liver transplant samples (r>or=0.900) than in the kidney transplant samples (r>or=0.849). No significant effect was found for sirolimus clearance or the blood hematocrit on the relationship between the results produced by both immunoassays and HPLC. CONCLUSION: The Innofluor FPIA is a valid alternative with an analogous performance to the MEIA for the therapeutic monitoring of sirolimus.


Subject(s)
Chromatography, High Pressure Liquid/methods , Fluorescence Polarization Immunoassay/methods , Immunoenzyme Techniques/methods , Immunosuppressive Agents/blood , Kidney Transplantation , Liver Transplantation , Sirolimus/blood , Spectrophotometry, Ultraviolet/methods , Humans , Particle Size , Reproducibility of Results
5.
Ups J Med Sci ; 113(1): 103-10, 2008.
Article in English | MEDLINE | ID: mdl-18521804

ABSTRACT

BACKGROUND: Published data on the performance of the new Dade Behring antibody conjugated magnetic immunoassay (ACMIA) for tacrolimus determination are scarce. The aim of this study was to compare the results obtained using the ACMIA and Abbott microparticle enzyme immunoassay (MEIA), which is the most widely used method for therapeutic tacrolimus monitoring. METHODS: Trough tacrolimus concentrations were determined in 305 blood samples from kidney (n=138) and liver (n=167) transplant recipients using the ACMIA and MEIA immunoassays. The MEIA results were corrected for hematocrit values lesser than 30% and higher than 40% (Hermida et al. Clin Lab 2005; 51: 43-45). RESULTS: The obtained ACMIA within- and between-run variation coefficients (<10.8%) were acceptable. In the comparison between ACMIA and MEIA results in the blood samples studied, the regression equation was: ACMIA=1.02MEIA+0.29 (r=0.912, p<0.001), with an acceptable difference between the means (8.13+/-0.53 ng/mL vs. 7.62+/-0.50 ng/mL). However, in accordance with the well-established interference of the hematocrit on the MEIA results, a highly significant negative correlation between the MEIA/ACMIA ratio and the hematocrit values was obtained (r=-0.585, p<0.001). When the MEIA results were corrected according to the hematocrit (MEIAHtC), the regression with ACMIA levels was: ACMIA=1.08MEIAHtC-0.09 (r=0.926, p<0.001). This equation was analogous to that obtained between ACMIA and MEIA tacrolimus concentrations in the 164 blood samples with hematocrit of 30-40%. CONCLUSIONS: ACMIA is an acceptable option for therapeutic tacrolimus monitoring, with an important decrease in technician time in relation to the widely used MEIA.


Subject(s)
Immunoassay/methods , Immunosuppressive Agents/blood , Kidney Transplantation , Liver Transplantation , Tacrolimus/blood , Humans , Reproducibility of Results
6.
Clin Biochem ; 41(12): 1002-7, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18474233

ABSTRACT

OBJECTIVES: The use of new antipsychotic drugs is associated with an increased risk of diabetes and metabolic syndrome, and the routine monitoring of blood lipids during treatment has been recommended. Recently, a new formula for the estimation of low-density lipoprotein (LDL) cholesterol from total cholesterol and triglycerides has been proposed by Anandaraja et al. (Int J Cardiol 2005; 102: 117), and the aim of our study was its evaluation in schizophrenic patients treated with antipsychotic drugs. MATERIALS AND METHODS: In 487 serum samples from schizophrenic patients treated with clozapine in polytherapy, the concentrations of LDL cholesterol were determined by agar gel electrophoresis and the formula of Friedewald et al. (Clin Chem 1972; 18: 499), and compared with the results of the Anandaraja's formula. RESULTS: A higher correlation and lower error of the estimate of the electrophoresis results was found with those of Friedewald (r=0.940, ma68=0.17 mmol/L) than those of Anandaraja (r=0.811, ma68=0.31 mmol/L). Similar results were obtained on making a dichotomy of the patients with and without metabolic syndrome lipid profile. A highly significant correlation was found between the high-density lipoprotein (HDL) cholesterol levels and the Anandaraja/Electrophoresis (r=0.817, p<0.001) and Anandaraja/Friedewald (r=0.977, p<0.001) ratios. CONCLUSIONS: According to our data, Anandaraja's formula tends towards an overestimation or underestimation of LDL cholesterol levels, depending on whether the HDL cholesterol levels are high or low, which may be clinically significant. These results do not support the proposed better accuracy of the Anandaraja's than the Friedewald's formula.


Subject(s)
Antipsychotic Agents/adverse effects , Cholesterol, LDL/blood , Clozapine/adverse effects , Schizophrenia/blood , Schizophrenia/drug therapy , Adult , Aged , Algorithms , Antipsychotic Agents/therapeutic use , Biomarkers/blood , Cholesterol, HDL/blood , Clozapine/therapeutic use , Electrophoresis, Agar Gel , Female , Humans , Linear Models , Male , Metabolic Syndrome/blood , Metabolic Syndrome/chemically induced , Middle Aged , Risk Factors , Triglycerides/blood
7.
Ups J Med Sci ; 113(2): 171-80, 2008.
Article in English | MEDLINE | ID: mdl-18509811

ABSTRACT

BACKGROUND: The proposed action mechanism and pharmacological activity of carbamazepine (CBZ) and its major metabolite, carbamazepine-10,11-epoxide (CBZE), are the same. The aim of our study was the investigation of the effect of concomitant antiepileptic treatment and renal insufficiency on the relative proportions of serum CBZ and CBZE. METHODS: Serum trough steady-state CBZ and CBZE concentrations were determined by high-performance liquid chromatography (HPLC) in 140 epileptic patients treated with CBZ in monotherapy (n=100) and polytherapy with phenytoin, phenobarbital and valproate (n=40). The levels of CBZ were also determined using the Dade Behring enzyme multiplied immunoassay technique (EMIT). The glomerular filtration rate (GFR) was estimated from serum cystatin C using the Dade Behring nephelometric immunoassay. RESULTS: The CBZE/CBZ and CBZ+CBZE/CBZEMIT ratios were significantly increased in 7 cases (3 in monotherapy and 4 in polytherapy) with GFR<60 mL/min/1.73m2 in relation to the patients treated in monotherapy or polytherapy having normal or mildly decreased renal function (p<0.001). CONCLUSIONS: In patients with moderate to severe renal insufficiency the relative proportion of CBZE with respect to the parent drug is significantly increased. In these cases, the CBZ concentrations obtained using the EMIT, or other immunoassays having low CBZE cross-reactivity, may have an inadequate diagnostic efficiency.


Subject(s)
Anticonvulsants/blood , Carbamazepine/blood , Renal Insufficiency/blood , Adolescent , Adult , Aged , Aged, 80 and over , Anticonvulsants/administration & dosage , Anticonvulsants/chemistry , Carbamazepine/administration & dosage , Carbamazepine/chemistry , Child , Child, Preschool , Chromatography, High Pressure Liquid , Drug Monitoring , Female , Humans , Male , Middle Aged , Spectrophotometry, Ultraviolet
8.
Clin Biochem ; 41(7-8): 603-6, 2008 May.
Article in English | MEDLINE | ID: mdl-18280253

ABSTRACT

OBJECTIVE: Therapeutic drug monitoring of clozapine may be useful for the clinical management of schizophrenic patients treated with this atypical antipsychotic drug. The aim of our study was the evaluation of three models for the prediction of steady-state trough clozapine concentration. PATIENTS AND METHODS: The trough serum concentrations of clozapine and norclozapine were determined by high-performance liquid chromatography in 296 samples from a group of 21 schizophrenic patients selected for their good therapeutic compliance. Also, the predicted clozapine concentrations were estimated by applying the models of Oyewumi et al. (Ther Drug Monit 1995; 17: 137), Perry et al. (Biol Psychiatry 1998; 44: 733) and Rostami-Hodjegan et al. (J Clin Psychopharmacol 2004; 24: 70). RESULTS: The efficiency for the accurate estimation of clozapine concentrations as subtherapeutic (<240 ng/mL), therapeutic (240-750 ng/mL) or supratherapeutic (>750 ng/mL), using the models of Oyewumi et al., Perry et al., and Rostami-Hodjegan et al., was 82%, 71% and 77% respectively. CONCLUSIONS: The predictive model of Oyewumi et al., which shows an easy calculation way and the greater diagnostic efficiency, may be of clinical value for the prediction of clozapine concentration or the dose required to achieve a specified concentration.


Subject(s)
Clozapine/administration & dosage , Clozapine/blood , Models, Biological , Adult , Aged , Dose-Response Relationship, Drug , Drug Monitoring/methods , Drug Monitoring/standards , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Smoking/blood
9.
Ther Drug Monit ; 30(1): 41-5, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18223461

ABSTRACT

At present, the determination of steady-state trough serum/plasma concentrations of clozapine is considered a useful tool for the clinical management of schizophrenic patients treated with this drug. In a previously published study, it was indicated that only plasma should be used to avoid a significant underestimation of clozapine and norclozapine concentrations; however, a formal evaluation of this topic has still not been made, and a consensus on the use of plasma or serum for therapeutic clozapine monitoring may be desirable. Paired samples of serum and plasma (K3EDTA solution contained in Vacutainer tubes) were obtained from 40 schizophrenic patients, and clozapine and norclozapine concentrations were determined by high-performance liquid chromatography. For the parent drug and its metabolite, serum concentrations were higher than in plasma (approximately 7%), although the correction of plasma concentrations in function of hematocrit values reduced this difference to 3%. High correlation coefficients were found between the serum and uncorrected or corrected plasma clozapine concentrations (r = 0.996, P < 0.001), with clinically acceptable differences between the means and standard error of the estimate and consequently with transferability of the results. The clozapine and norclozapine concentrations in five lithium heparin-containing plasma samples (371.9 +/- 226.7 ng/mL and 217.9 +/- 113.1 ng/mL) were analogous to the corresponding hematocrit-corrected EDTA-containing plasma values (374.4 +/- 225.4 ng/mL and 223.5 +/- 115.2 ng/mL), with correlation coefficients of r > or = 0.998 (P < 0.001). Serum or plasma samples may be used for the therapeutic monitoring of clozapine, and no practical advantages have been found with regard to the stability of the drug or imprecision obtained by using either type of biological matrix.


Subject(s)
Antipsychotic Agents/blood , Clozapine/analogs & derivatives , Clozapine/blood , Schizophrenia/drug therapy , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/therapeutic use , Chromatography, High Pressure Liquid , Clozapine/pharmacokinetics , Clozapine/therapeutic use , Humans , Plasma , Serum
10.
Clin Lab ; 53(7-8): 433-8, 2007.
Article in English | MEDLINE | ID: mdl-17821947

ABSTRACT

Several factors have been considered in relation to the free radical formation in schizophrenia, such as the disease itself, drug treatment and smoking. Several chemicals and drugs may cause damage to the renal tubules by different subcellular mechanisms including oxidative stress, and the aim of our study was the investigation of tubular dysfunction in schizophrenic patients. The urinary excretion of beta-N-acetylhexosaminidase (Hex) and its isoenzymes Hex A and Hex B, alpha1-microglobulin, albumin, total proteins and fractionated porphyrins were determined in 45 schizophrenic patients treated with first- and second-generation antipsychotics. In 7 patients, an increase in proteinuria of tubular origin was found, and in one as a result of mixed glomerular/tubular origin. The group of patients had a significantly higher level of excretion than the control group (n = 54) of total Hex (p < 0.001), Hex A (p < 0.05), Hex B (p < 0.001) and the relative proportion of this isoenzyme (p < 0.001). In some cases with normal levels of total Hex and urinary alpha1-microglobulin, the proportion of Hex B was already increased. Significant correlations were found for total Hex and its isoenzymes with alpha1-microglobulin (p < 0.001). Also, the porphyrins had significant correlations with total Hex (p < 0.001), Hex A (p < 0.05), Hex B (p < 0.005) and alpha1-microglobulin (p < 0.001). In the group of patients studied, it was possible to reveal early tubular cell damage (affected structural integrity) with increased excretion of Hex B, possibly mediated by free radicals, previous to the decrease in tubular reabsorption of proteins with low molecular mass filtered by the glomerulus (affected functional integrity).


Subject(s)
Alpha-Globulins/urine , Antipsychotic Agents/therapeutic use , Fanconi Syndrome/complications , Kidney Tubules/pathology , Porphyrins/urine , Schizophrenia/complications , beta-N-Acetylhexosaminidases/urine , Adult , Aged , Female , Hexosaminidase A , Hexosaminidase B , Humans , Isoenzymes/urine , Male , Middle Aged , Proteinuria/diagnosis , Proteinuria/etiology , Proteinuria/urine , Reference Values , Schizophrenia/drug therapy
11.
Article in English | MEDLINE | ID: mdl-17690747

ABSTRACT

BACKGROUND: Carbamazepine (CBZ) occasionally causes haematological disorders such as thrombocytopenia, and recently a case of oxcarbazepine (OXCBZ)-induced thrombocytopenia has been described. The aim of our study was blood platelet count determination in epileptic patients treated with CBZ and OXCBZ, and its relationship with the dose and serum levels of these drugs and its metabolites. METHODS: The serum levels of CBZ and its epoxide, and the pharmacologically active monohydroxy derivative of OXCBZ were determined in 137 patients treated with CBZ, and 60 patients treated with OXCBZ. The platelet count, mean platelet volume, and platelet size distribution width were also determined. RESULTS: The difference between the platelet counts of the patient groups treated with CBZ and OXCBZ was not significant. No significant correlations between the platelet count and serum levels of the administered antiepileptic drugs and their metabolites were found. However, significant negative correlations between the platelet count and the daily doses of CBZ and OXCBZ were obtained (p<0.01). In 5 cases (4 treated with CBZ and 1 with OXCBZ) the platelet count was <150 x 10(9)/l. CONCLUSIONS: In accordance with the mean platelet volume and platelet distribution width, the thrombocytopenia observed in some of the patients studied was due to a hyper-destruction of peripheral blood platelets. However, the results obtained suggest that the mechanism of CBZ or OXCBZ-induced thrombocytopenia is not due to a direct toxicity of these drugs or their major metabolites on the circulating platelets. Although, the patients treated with OXCBZ shown a lower prevalence for thrombocytopenia (1.7%) than those treated with CBZ (2.9%), the routine platelet count monitoring in patients treated with both drugs may be recommended.


Subject(s)
Anticonvulsants/administration & dosage , Carbamazepine/analogs & derivatives , Carbamazepine/administration & dosage , Epilepsy/blood , Platelet Count , Adolescent , Adult , Aged , Aged, 80 and over , Anticonvulsants/pharmacokinetics , Carbamazepine/pharmacokinetics , Child , Child, Preschool , Epilepsy/drug therapy , Female , Humans , Male , Middle Aged , Oxcarbazepine
13.
J Clin Lab Anal ; 21(2): 119-23, 2007.
Article in English | MEDLINE | ID: mdl-17385679

ABSTRACT

The debate continues regarding the possible interference of phenytoin metabolites in phenytoin immunoassays, and its clinical importance for patients with renal failure. The aim of this study was to compare the results obtained using the Abbott fluorescence polarization immunoassay (FPIA), Dade enzyme-multiplied immunoassay technique (EMIT), and high-performance liquid chromatography (HPLC) to establish the significance of the differences in conditions of renal failure. Thirty-six adult patients who had been treated with phenytoin and whose renal function ranged from normal to severely impaired were chosen for this study. In accordance with previously established validation criteria for analytical methods for the determination of drugs, a 15% bias from the HPLC phenytoin values was considered an acceptable limit. The mean (+/-SEM) glomerular filtration rate (GFR) of the patients was 37.5+/-4.6 mL/min (range = 10-102 mL/min). The mean values found using FPIA (10.8+/-1.2 microg/mL) and EMIT (10.8+/-1.3 microg/mL) presented acceptable deviations with respect to HPLC (10.5+/-1.2 microg/mL), and a high correlation was found among the results (N = 36) of the different methods (r > or = 0.987, P < 0.001). An FPIA deviation above the 15% bias limit with respect to HPLC was found only in two cases with very low serum phenytoin concentrations and low GFR values (< 20 mL/min), although it does not appear to be important in terms of adjusting drug dosage. According to our data, FPIA and EMIT gave accurate results for total phenytoin in serum samples from patients with renal failure.


Subject(s)
Acute Kidney Injury/blood , Chromatography, High Pressure Liquid , Immunoassay/methods , Phenytoin/blood , Renal Insufficiency, Chronic/blood , Adult , Aged , Aged, 80 and over , Female , Glomerular Filtration Rate , Humans , Male , Middle Aged , Reproducibility of Results
14.
Clin Lab ; 52(9-10): 483-90, 2006.
Article in English | MEDLINE | ID: mdl-17078475

ABSTRACT

Determination of the glomerular filtration rate (GFR) is important for the drug dosage adjustment and clinical management of patients. The aim of our study was the comparison of estimated GFR values from serum creatinine (eGFRcreatinine) and cystatin C (eGFRcystatin C) in patients with impaired creatinine production. A total of 564 serum samples from patients with kidney disease (n=179), liver (n=71) and kidney (n=182) transplants, critically ill patients (n=82) and healthy subjects (n=50) were analyzed for serum creatinine and cystatin C. The creatinine production rate (CPR) was significantly lower in the different groups of patients than in the control group (p<0.001). A negative correlation was found between the eGFRcreatinine/eGFRcystatin C ratio and CPR (r= -0.964, p<0.001). For CPR higher than 800 mg/24h both procedures for estimating the GFR classified values higher and lower than 60 mL/min with an acceptable agreement; however, for CPR less than 800 mg/24h the eGFRcreatinine led to false negatives in a high number of cases with eGFRcystatin C <60 mL/min.


Subject(s)
Creatinine/blood , Creatinine/metabolism , Cystatins/blood , Glomerular Filtration Rate , Kidney Diseases/diagnosis , Kidney/physiopathology , Adult , Aged , Aged, 80 and over , Cystatin C , Female , Humans , Kidney Diseases/physiopathology , Kidney Transplantation , Liver Transplantation , Male , Middle Aged , Prognosis
15.
Ther Drug Monit ; 28(3): 326-31, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16778715

ABSTRACT

Dosage regimes of aminoglycosides and vancomycin are modified according to the glomerular filtration rate (GFR). In 130 hospitalized patients who were administered amikacin, gentamicin, tobramycin, and vancomycin by intermittent intravenous infusion, we compared the predicted GFR values from the serum concentrations of creatinine (Cockcroft and Gault. Nephron. 1976;16:31-41) and cystatin C (Larsson et al. Scand J Clin Lab Invest. 2004;64:25-30) with respect to their relevance for proper dosage. In 83% and 67% of the cases, respectively, the serum levels of albumin and cholinesterase were below the corresponding lower limit of the reference range. The ratio of creatinine/cystatin C concentrations presented significant correlations with the predicted rate of creatinine production (r=0.762, P<0.001), serum albumin concentration (r=0.205, P<0.05), and catalytic serum concentrations of cholinesterase (r=0.207, P<0.05), gamma glutamyltransferase (r=-0.273, P<0.01), and alkaline phosphatase (r=-0.289, P<0.01). The GFR (mean+/-SD; median) predicted by the serum creatinine (84.0+/-35.1 mL/min/1.73 m; 82.6 mL/min/1.73 m) was significantly higher (P<0.001) than that predicted by the serum cystatin C (53.1+/-30.2 mL/min/1.73 m; 44.9 mL/min/1.73 m). The ratio between the GFR values predicted by creatinine and cystatin C had a highly significant negative correlation with the rate of creatinine production (r=-0.912, P<0.001). Furthermore, significant differences were found for the peak concentrations and clearances of amikacin and vancomycin estimated by means of the Abbottbase Pharmacokinetic Systems program, and using the GFR values predicted by the serum creatinine and cystatin C (P<0.005). In patients with hepatic dysfunction, the clearance of creatinine predicted by the Cockcroft-Gault formula leads to a significant overestimation of the GFR. Cystatin C seems to be a valid alternative as a GFR marker with regard to drug dose adjustment in these cases.


Subject(s)
Aminoglycosides/administration & dosage , Aminoglycosides/pharmacokinetics , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Cystatins/blood , Glomerular Filtration Rate , Adolescent , Adult , Aged , Aged, 80 and over , Amikacin/administration & dosage , Amikacin/pharmacokinetics , Creatinine/blood , Cystatin C , Drug Monitoring , Female , Gentamicins/administration & dosage , Gentamicins/pharmacokinetics , Hepatic Insufficiency/complications , Humans , Male , Metabolic Clearance Rate , Middle Aged , Tobramycin/administration & dosage , Tobramycin/pharmacokinetics , Vancomycin/administration & dosage , Vancomycin/pharmacokinetics
16.
J Pharmacol Sci ; 99(4): 323-8, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16314692

ABSTRACT

The action of some anticonvulsant drugs as the causal agents of attacks of acute porphyria has been widely documented in the literature. However, little attention has been paid to the effect of these drugs on the urinary excretion of porphyrins in non-porphyric subjects. In a sample of 82 epileptic patients treated with phenobarbital (n = 54), phenytoin (n = 64), carbamazepine (n = 33), and valproate (n = 8), the daily doses were expressed according to a drug score that would reflect the capacity of these drugs as enzymatic inducers when administered in polytherapy. A significantly increased urinary excretion of D-glucaric acid (DGA) and porphyrins was found in this group of patients (P<0.001), with coproporphyrin being the major fraction in all cases (>60%). Urinary DGA had a highly significant correlation with the drug score (r = 0.783, P<0.001); however, no significant correlations were found between the urinary porphyrins and DGA (r = 0.005) or the drug score (r = 0.053). Neither was any significant relationship found between the urinary porphyrins and the serum activity of 5'-nucleotidase (r = 0.066) or the presence of a cholestasis objectivized through the presence of the isoform of gamma-glutamyltransferase with beta-globulins electrophoretic mobility. However, in a group of 10 patients a significant correlation was found between the urinary excretion of porphyrins and beta-N-acetylhexosaminidase (r = 0.790, P<0.01). Therefore, it does not appear that the liver enzyme induction, or even a subclinical cholestasis, produced by the antiepileptic drugs administered to these patients may serve to explain the increase in the urinary excretion of porphyrins. A possible renal origin is proposed for the increase of urinary porphyrins in these cases.


Subject(s)
Anticonvulsants/adverse effects , Epilepsy/urine , Porphyrins/urine , Adult , Anticonvulsants/therapeutic use , Cholestasis/urine , Enzyme Induction/drug effects , Enzymes/urine , Epilepsy/drug therapy , Female , Glucaric Acid/urine , Humans , Male , Middle Aged , Porphyrias/urine , Pyridoxal Phosphate/pharmacology , Transaminases/blood
17.
Kidney Int ; 68(3): 948-54, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16105025

ABSTRACT

BACKGROUND: The relationship between the progress of tubular damage and renal insufficiency in autosomal-dominant polycystic kidney disease (ADPKD) is a subject of doubtless interest, and is the object of this present work. METHODS: A total of 92 adult ADPKD patients of both genders were studied, none of which presented end-stage renal disease (ESRD), and classified according to an ultrasound score based on kidney size and number of cysts. Urinary albumin and beta-N-acetylhexosaminidase (Hex) and its isoenzymes were determined, together with serum glutathione peroxidase, cystatin C, creatinine, and urea. RESULTS: A frequent elevation of the urinary Hex was found and an alteration of its isoenzymatic profile, with 31% of the normotensive patients with normoalbuminuria already presenting an increased proportion of Hex B isoenzyme. Keeping age constant, a partial significant correlation was found between the ultrasound score and the proportion of Hex B (r = 0.352, P < 0.05), but not with albuminuria or cystatin C. In 42 patients the different biochemical variables were again determined after 1 year, finding that in the 13 normotensive patients with normoalbuminuria there had been a significant decrease in the concentration of cystatin C (P < 0.05), and a significant increase in the urinary excretion of albumin and Hex B isoenzyme (P < 0.05). By the other hand, in the other 29 patients with micro- or macroalbuminuria and hypertension, no significant differences were found. CONCLUSION: The results point toward an important participation of tubular damage in the pathogenesis of this disease. It may also be suggested that in normotensive and normoalbuminuric ADPKD patients, a gradual increase of glomerular filtration would be produced. After the start of hypertension and microalbuminuria, the glomerular filtration rate (GFR) would decrease progressively, although more slowly.


Subject(s)
Albuminuria/diagnosis , Hypertension, Renal/diagnosis , Polycystic Kidney, Autosomal Dominant/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Albuminuria/blood , Albuminuria/urine , Biomarkers/blood , Biomarkers/urine , Creatine/blood , Cystatin C , Cystatins/blood , Female , Glomerular Filtration Rate , Glutathione Peroxidase/blood , Hexosaminidase B , Humans , Hypertension, Renal/blood , Hypertension, Renal/urine , Isoenzymes/urine , Male , Middle Aged , Polycystic Kidney, Autosomal Dominant/blood , Polycystic Kidney, Autosomal Dominant/urine , Urea/blood , beta-N-Acetylhexosaminidases/urine
18.
J Pharmacol Sci ; 97(4): 489-93, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15840952

ABSTRACT

In patients with hypoalbuminemia, the total serum concentration of valproic acid may offer poor clinical information; however, very few clinical laboratories routinely analyze the free concentration of the drug. The aim of this study was to design a procedure to normalize the total concentration of valproic acid according to the level of serum albumin and using previously published free fraction values. In 121 adult patients, with albumin levels of 18 - 41 g/L, the total concentration of valproic acid was normalized using the derived equation: C(N) = alpha(H)C(H)/6.5, where alpha(H) is the free fraction of the drug corresponding to the patient's particular albuminemia and C(H) is the total concentration of valproic acid. The value of 6.5 corresponds to the free fraction of the drug for a serum albumin of 42 g/L (percentile 50 of the reference range). For total concentrations lower than 75 mg/L, the predicted normalized valproic acid concentrations were reasonably concordant with the observed normalized concentrations calculated using the data from a protein-binding study. In a significant number of cases, subtherapeutic concentrations of the drug became therapeutic and even supratherapeutic when corrected according to the albumin levels. Furthermore, cases with therapeutic drug concentrations frequently became supratherapeutic when normalized. The limitations and clinical applications of the proposed formula for normalizing the total concentration of valproic acid are presented. It is concluded that it may be useful for the posological management of hypoalbuminemic patients when the free concentration of the drug is not available, and decisions have to be made based on the total serum concentration.


Subject(s)
Blood Chemical Analysis/methods , Hypoalbuminemia/blood , Valproic Acid/blood , Adult , Blood Chemical Analysis/statistics & numerical data , Humans , Middle Aged , Protein Binding , Reference Values , Serum Albumin/analysis
19.
Clin Lab ; 51(1-2): 43-5, 2005.
Article in English | MEDLINE | ID: mdl-15719703

ABSTRACT

Recently, the possible interference of hematocrit on the results of the Abbott Tacrolimus II microparticle enzyme immunoassay (MEIA) has been described, although its significance in clinical practice has not been established as yet. The aim of our study was the evaluation of the significance of this analytical interference in therapeutic tacrolimus monitoring. In 1121 cases selected at random over a 9-month period from kidney (n=379) and liver (n=742) transplant patients, an estimation was made of errors caused by the hematocrit in the results provided by the Tacrolimus II MEIA. In accordance with the available data, it was assumed that an error may be produced beyond the range of hematocrit values from 30% to 40%, either positive or negative respectively, of 3% per unit of hematocrit. The acceptance criterion for accuracy was no more than 15% of deviation (error) with respect to the experimental concentration of tacrolimus. In 160 cases (14.3%) the results of the Tacrolimus II MEIA would not be acceptable due to hematocrit-dependent errors, both with positive (hematocrit <25%) in 108 cases (9.7%) and negative values (hematocrit >45%) in 52 cases (4.6%). The obtained results demonstrate the practical interest of the subject, although additional studies are required in order to validate our approach to the clinical significance of this hematocrit-dependent interference in the Tacrolimus MEIA.


Subject(s)
Clinical Medicine/methods , Drug Monitoring/methods , Hematocrit , Immunoenzyme Techniques/methods , Immunosuppressive Agents/blood , Tacrolimus/blood , Artifacts , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Liver Transplantation , Reproducibility of Results , Tacrolimus/therapeutic use
20.
J Pharm Pharm Sci ; 7(3): 353-8, 2004 Nov 15.
Article in English | MEDLINE | ID: mdl-15576017

ABSTRACT

PURPOSE: The increase of serum activity of gamma-glutamyltranferase (gammaGT) through the action of enzyme-inducing anticonvulsant drugs has been widely documented; however, the behaviour of its multiple forms and its relationship with the degree of enzyme induction has received little coverage. This subject is the major aim of our paper. METHODS: An electrophoretic study of the serum gammaGT isoforms was made in 90 adult epileptic patients under chronic treatment with phenobarbital, phenytoin and carbamazepine in polytherapy. RESULTS: A significant correlation was found (p<0.001) between the drug score and urinary excretion of D-glucaric acid (DGA) (r=0.773), total gammaGT (r=0.382), gammaGT1 (r=0.398) and gammaGT2 (r=0.361). In a group of 11 patients with the gammaGT3 isoforms, considered a sensitive test for cholestasis, serum activities of total gammaGT, gammaGT1, gammaGT2 and 5 -nucleotidase were found that were significantly higher than in the 79 patients without the gammaGT3 isoform (p<0.001); however, for the drug score and excretion of DGA, no significant differences were found, suggesting a similar degree of enzyme induction in both groups of patients. CONCLUSIONS: The presence of cholestasis, at least biochemically detectable in some of these patients, appears to be a factor of paramount importance when interpreting the effect of enzyme-inducing anticonvulsant drugs on serum gammaGT. This fact may contribute towards explaining its highly varied response to the administration of these drugs.


Subject(s)
Anticonvulsants/pharmacology , Epilepsy/blood , Isoenzymes/blood , gamma-Glutamyltransferase/blood , Adult , Anticonvulsants/therapeutic use , Carbamazepine/pharmacology , Carbamazepine/therapeutic use , Epilepsy/drug therapy , Epilepsy/enzymology , Female , Humans , Male , Phenobarbital/pharmacology , Phenobarbital/therapeutic use , Phenytoin/pharmacology , Phenytoin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...